Theranostics Trial Center Receives $1.4 Million for Groundbreaking Precision Medicine Initiative
The Theranostics Trial Center (TTC) at Karolinska University Hospital and the Karolinska Institutet has received a significant grant of over $1.4 million from Vinnova, the Swedish government agency for innovation, as part of the "Future Precision Medicine" initiative. TTC’s proposal, "Theranostic Trial Alliance: Image-Guided Diagnostics and Therapy with Targeted Radiopharmaceuticals," was among the most innovative and promising of the 53 applications submitted, with the potential to transform Swedish healthcare.
The project aims to create a robust innovation environment where precision medicine and groundbreaking treatments with radiolabeled targeted drugs can be developed and implemented in clinical practice. The newly formed Theranostic Trial Alliance (TTA) Sweden is a collaborative effort involving Swedish hospitals, researchers, academia, pharmaceutical companies, and the Life Sciences sector. Through this partnership, TTA seeks to accelerate the translation of the latest research advances in theranostics—an approach that combines diagnostics and therapy into a single process to more effectively target specific cancer types.
“This grant is a significant advancement for our research and a clear signal that Sweden is committed to becoming a leading nation in the rapidly growing field of theranostics,” says Professor Rimma Axelsson, Scientific Director of the Theranostics Trial Center at Karolinska University Hospital.
“Our goal is to fulfill the promise of precision medicine—offering tailored diagnostics and treatments that can improve survival and quality of life for critically ill patients.”
With support from Vinnova, the Theranostic Trial Alliance Sweden can establish itself as a powerful hub for Swedish innovation in precision medicine. The partnership is expected to pave the way for new treatment options for cancer patients and open doors to more effective and personalized treatment strategies.